Literature DB >> 15485598

Antihypertensive drugs and the kidney.

Mitra K Nadim1, Renee Dua, Vito M Campese.   

Abstract

In the United States, 50 million Americans are estimated to have hypertension. Over the past several decades, it has become clear that hypertension is both a cause and a consequence of kidney disease. In contrast to the striking decline in mortality rates from both stroke and coronary heart disease, the prevalence of hypertension as a cause of end-stage renal disease (ESRD) has increased such that it is now the second most common cause of ESRD in the United States. Hypertension and proteinuria occur in most patients with chronic kidney disease and are risk factors for faster progression of kidney disease. Antihypertensive agents reduce blood pressure and urine protein excretion and slow the progression of kidney disease. The level of blood pressure achieved and use of renin-angiotensin-aldosterone system-blocking agents is critical for delaying progression of renal disease in all ethnic groups.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15485598     DOI: 10.1007/s11886-004-0046-3

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  50 in total

Review 1.  Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications.

Authors:  M Epstein
Journal:  Am J Kidney Dis       Date:  2001-04       Impact factor: 8.860

2.  Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM.

Authors:  G Crepaldi; Q Carta; G Deferrari; R Mangili; R Navalesi; F Santeusanio; A Spalluto; A Vanasia; G M Villa; R Nosadini
Journal:  Diabetes Care       Date:  1998-01       Impact factor: 19.112

3.  Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

Authors: 
Journal:  Lancet       Date:  1997-06-28       Impact factor: 79.321

4.  Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Northern Italian Cooperative Study Group.

Authors:  F Locatelli; D Marcelli; M Comelli; D Alberti; G Graziani; G Buccianti; B Redaelli; A Giangrande
Journal:  Nephrol Dial Transplant       Date:  1996-03       Impact factor: 5.992

5.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

6.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

7.  Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.

Authors:  R Rocha; P N Chander; K Khanna; A Zuckerman; C T Stier
Journal:  Hypertension       Date:  1998-01       Impact factor: 10.190

8.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.

Authors:  Naoyuki Nakao; Ashio Yoshimura; Hiroyuki Morita; Masyuki Takada; Tsuguo Kayano; Terukuni Ideura
Journal:  Lancet       Date:  2003-01-11       Impact factor: 79.321

9.  Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis.

Authors:  B L Kasiske; R S Kalil; J Z Ma; M Liao; W F Keane
Journal:  Ann Intern Med       Date:  1993-01-15       Impact factor: 25.391

10.  The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.

Authors:  S Klahr; A S Levey; G J Beck; A W Caggiula; L Hunsicker; J W Kusek; G Striker
Journal:  N Engl J Med       Date:  1994-03-31       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.